Article Text

Download PDFPDF

355 TCR γδ+ TIL from patients with pancreatic cancer recognize autologous tumor cells restricted by CD1d
  1. Joana Lerias1,
  2. Patrícia António1,
  3. Jéssica Kamiki1,
  4. Rodrigo Eduardo1,
  5. Sara Cascais1,
  6. Bernardo Marinheiro1,
  7. Eric De Sousa1,
  8. Carolina Gorgulho1,
  9. Andreia Maia1,
  10. Mireia Castillo-Martin1,
  11. Markus Buechler1,
  12. Carlos Carvalho1,
  13. Antonio Beltran1,
  14. Sam Jeong2,
  15. Ridong Chen2 and
  16. Markus Maeurer1
  1. 1Champalimaud Center for the Unknown, Lisbon, Portugal
  2. 2Human Cell Inc, Naperville, IL, USA


Background Pancreatic cancer is the 7th leading cause of cancer-related deaths worldwide. Treatment options are still limited; immunotherapeutic approaches using tumor infiltrating lymphocytes (TIL) represent a viable option for PDAC patients. TILs from PDAC lesions will include αβ+ and γδ+ T-cells, that recognize tumor cells restricted by non-classical MHC I molecules.1,2 γδ+ TILs are generally associated with a more favorable prognosis3 and present promising candidates for adoptive cellular therapy as cellular products, or by cloning the molecular blueprint of cancer-specific TCRs that could be transferred into recipient immune cells. The study focused on the expansion of TIL containing TCR γδ+, molecular analysis of TCR γδ+ cells, and testing anti-tumor directed TIL specificity defined by IFN-gamma production upon NRLP3 pathway stimulation.

Methods Freshly harvested tumor tissue was used to propagate TIL using cytokines in combination with an NRLP3 pathway activator for 2-3 weeks. γδ+ T-cell expansion and T-cell activation/exhaustion were tested by flow cytometry and autologous tumor recognition assays were performed using blocking mAbs and IFN-gamma as the biological readout; molecular recognition analysis was performed using synthetic peptides derived from tumor exome sequencing. TCR deep sequencing was performed in sorted TCR γδ+ TIL. Tumor infiltration by TCR γδ+ was gauged by immunohistochemistry and spatial transcriptomics.

Results NRLP3 stimulation results in increased TCR γδ+ cells which – after sorting (>90% purity) – recognized autologous and allogeneic pancreatic cancer cells in a CD1d-restricted fashion defined by IFN-gamma production. TCR sequencing revealed a focused TCR repertoire with unusual Vgamma3 and Vgamma8 usage. NRLP3 stimulation increased the frequency of αβ+ T-cells against autologous tumor cells and mutant target epitopes defined by IFN-gamma production, abrogated with an NRLP3 inhibitor. Spatial transcriptomics revealed co-localization of CD1d and perforin+granzymeA+granzymeB γδ+ T-cells; TCR-sequencing of PDAC tissue and corresponding TIL exhibited an oligoclonal TCR repertoire. NRLP3 stimulation increased mRNA and protein expression of CXCL9 and CXCL10, which facilitates tissue invasion and favored CD1d restricted recognition of damaged mitochondria by γδ+ T-cells.

Conclusions NRLP3 pathway stimulation increased tumor-reactive and mutant epitope specific TILs, increased expression of chemokines facilitating tissue invasion and expansion of γδ+ TIL engaged in surveillance of damaged mitochondria. This allows a clinically relevant expansion of TIL for patients with PDAC that recognized tumor associated antigens restricted by classical and non-classical MHC molecules. CD1d restricted and tumor-reactive γδ TCRs can be used as blueprints for anti-cancer directed receptors that could be transferred into recipient cells for active cellular immunotherapy for patients with PDAC.


  1. Zhao Y, Niu C, Cui J. Gamma-delta (γδ) T cells: friend or foe in cancer development? J Transl Med. 2018; 16(1):3

  2. Maeurer MJ, Martin D, Walter W, Liu K, Zitvogel L, Halusczcak K, Rabinowich H, Duquesnoy R, Storkus W, Lotze MT. Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin. J Exp Med. 1996; 183(4):1681-1696

  3. Lo Presti E, Pizzolato G, Corsale AM, Caccamo N, Sireci G, Dieli F, Meraviglia S. γδ T cells and Tumor Microenvironment: From Immunosurveillance to Tumor Evasion. Front Immunol. 2018; 9:1395

Ethics Approval This study was approved by the Champalimaud Foundation’s Ethics Committee. Research complied with the corresponding ethical principles and the applicable international, EU and national directive laws (EU Directive 2004/23/EC).

Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.